• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Genet . Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Nat Genet


. 2023 Mar 9.
doi: 10.1038/s41588-023-01307-z. Online ahead of print.
Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection


Jin Wei[SUP] #[/SUP][SUP] 1 2 [/SUP], Ajinkya Patil[SUP] #[/SUP][SUP] 3 4 5 [/SUP], Clayton K Collings[SUP] 3 4 [/SUP], Mia Madel Alfajaro[SUP] 1 2 [/SUP], Yu Liang[SUP] 6 7 [/SUP], Wesley L Cai[SUP] 8 [/SUP], Madison S Strine[SUP] 1 2 [/SUP], Renata B Filler[SUP] 1 2 [/SUP], Peter C DeWeirdt[SUP] 9 [/SUP], Ruth E Hanna[SUP] 9 [/SUP], Bridget L Menasche[SUP] 1 2 [/SUP], Arya Ökten[SUP] 1 2 [/SUP], Mario A Peña-Hernández[SUP] 1 2 [/SUP], Jon Klein[SUP] 2 [/SUP], Andrew McNamara[SUP] 1 2 [/SUP], Romel Rosales[SUP] 10 11 [/SUP], Briana L McGovern[SUP] 10 11 [/SUP], M Luis Rodriguez[SUP] 10 11 [/SUP], Adolfo García-Sastre[SUP] 10 11 12 13 14 [/SUP], Kris M White[SUP] 10 11 [/SUP], Yiren Qin[SUP] 15 16 17 [/SUP], John G Doench[SUP] 9 [/SUP], Qin Yan[SUP] 18 19 [/SUP], Akiko Iwasaki[SUP] 18 19 20 [/SUP], Thomas P Zwaka[SUP] 15 16 17 [/SUP], Jun Qi[SUP] 6 7 [/SUP], Cigall Kadoch[SUP] 21 22 23 [/SUP], Craig B Wilen[SUP] 24 25 26 [/SUP]



Affiliations

Abstract

Identification of host determinants of coronavirus infection informs mechanisms of viral pathogenesis and can provide new drug targets. Here we demonstrate that mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) chromatin remodeling complexes, specifically canonical BRG1/BRM-associated factor (cBAF) complexes, promote severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and represent host-directed therapeutic targets. The catalytic activity of SMARCA4 is required for mSWI/SNF-driven chromatin accessibility at the ACE2 locus, ACE2 expression and virus susceptibility. The transcription factors HNF1A/B interact with and recruit mSWI/SNF complexes to ACE2 enhancers, which contain high HNF1A motif density. Notably, small-molecule mSWI/SNF ATPase inhibitors or degraders abrogate angiotensin-converting enzyme 2 (ACE2) expression and confer resistance to SARS-CoV-2 variants and a remdesivir-resistant virus in three cell lines and three primary human cell types, including airway epithelial cells, by up to 5 logs. These data highlight the role of mSWI/SNF complex activities in conferring SARS-CoV-2 susceptibility and identify a potential class of broad-acting antivirals to combat emerging coronaviruses and drug-resistant variants.
 
Back
Top Bottom